AN2 Therapeutics Inc (ANTX)

Form 8-K - Current report

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at...

Form 4 - Statement of changes in beneficial ownership of securities

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Oral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus...

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities